Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 VENDOR SHARE ANALYSIS
2.8 MULTIVARIATE MODELING
2.9 PRODUCT TYPE TIMELINE CURVE
2.1 MARKET APPLICATION COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.1.1 INTRODUCTION
4.1.2 POLITICAL ANALYSIS
4.1.3 ECONOMIC ANALYSIS
4.1.4 SOCIAL ANALYSIS
4.1.5 TECHNOLOGICAL ANALYSIS
4.1.6 ENVIRONMENTAL ANALYSIS
4.1.7 LEGAL ANALYSIS
4.1.8 CONCLUSION
4.2 PORTER’S FIVE FORCES ANALYSIS
4.2.1 INTRODUCTION
4.2.2 INTENSITY OF COMPETITIVE RIVALRY (HIGH)
4.2.3 BARGAINING POWER OF BUYERS – HIGH
4.2.4 THREAT OF NEW ENTRANTS – MODERATE
4.2.5 THREAT OF SUBSTITUTE PRODUCTS – MODERATE
4.2.6 BARGAINING POWER OF SUPPLIERS – MODERATE
4.2.7 CONCLUSION
4.3 COMPANY EVALUATION QUADRANT
4.4 PATIENT FUNNEL METHODOLOGY (MANDATORY MODEL)
4.4.1 A BOTTOM-UP PATIENT FUNNEL WILL BE CONSTRUCTED
4.4.1.1 TOTAL SBS POPULATION
4.4.1.2 SBS-IF POPULATION
4.4.1.3 DIAGNOSED SBS-IF PATIENTS
4.4.1.4 TREATED SBS-IF PATIENTS
4.4.1.5 THERAPY-SPECIFIC PATIENT POOLS
4.4.1.6 THIS ENSURES PATIENT NUMBERS ARE DIRECTLY ESTIMATED, NOT INFERRED FROM MARKET SIZE
4.4.1.7 NORTH AMERICA PATIENT FUNNEL SEGMENTATION
4.4.1.8 TOTAL SBS POPULATION
4.4.1.9 ADULT SBS
4.4.1.10 PEDIATRIC SBS
4.4.1.11 SBS-IF POPULATION
4.4.1.12 TYPE 1 SBS-IF (ACUTE)
4.4.1.13 TYPE 2 SBS-IF (PROLONGED ACUTE)
4.4.1.14 TYPE 3 SBS-IF (CHRONIC)
4.4.1.15 DIAGNOSED PATIENT POPULATION
4.4.1.16 DIAGNOSED – HOSPITAL-BASED
4.4.1.17 DIAGNOSED – OUTPATIENT FOLLOW-UP
4.4.1.18 UNDIAGNOSED / MISCLASSIFIED
4.4.1.19 TREATED PATIENT POPULATION
4.4.1.20 ACTIVELY TREATED PATIENTS
4.4.1.21 UNTREATED / SUPPORTIVE-ONLY
4.4.2 TREATMENT-SPECIFIC PATIENT SEGMENTATION (CRITICAL)
4.4.2.1 PN-DEPENDENT PATIENT POPULATION (CORE SEGMENT)
4.4.2.2 FULLY PN-DEPENDENT
4.4.2.3 PARTIALLY PN-DEPENDENT
4.4.2.4 ICU PN-DEPENDENT (TYPE 1 ACUTE)
4.4.2.5 HOME PN-DEPENDENT
4.4.2.6 GLP-2 ANALOGUE TREATED PATIENTS
4.4.2.7 INCLUDES PATIENTS RECEIVING TEDUGLUTIDE
4.4.2.8 PIPELINE THERAPIES (E.G., APRAGLUTIDE)
4.4.2.9 SUB-SEGMENTATION
4.4.2.10 PN-DEPENDENT RECEIVING GLP-2
4.4.2.11 PN-WEANING PATIENTS
4.4.2.12 PEDIATRIC VS ADULT
4.4.2.13 SUPPORTIVE PHARMACOTHERAPY PATIENTS (ATTRIBUTABLE)
4.4.2.14 ANTI-DIARRHEAL USERS
4.4.2.15 PPI USERS
4.4.2.16 ANTIBIOTIC (SIBO) PATIENTS
4.4.2.17 MICRONUTRIENT-DEPENDENT PATIENTS
4.4.2.18 SURGICAL & TRANSPLANT PATIENTS
4.4.2.19 INTESTINAL LENGTHENING PROCEDURES
4.4.2.20 TRANSPLANT PATIENTS
4.4.2.21 POST-TRANSPLANT SURVIVORS
4.4.3 PATIENT SEGMENTATION BY DEPENDENCY STATUS (HIGHLY IMPORTANT)
4.4.3.1 PN-DEPENDENT POPULATION
4.4.3.2 CORE REVENUE-DRIVING SEGMENT
4.4.3.3 PN-WEANING POPULATION
4.4.3.4 GLP-2 RESPONDERS
4.4.3.5 PN-INDEPENDENT POPULATION
4.4.3.6 MAINTAINED ON ORAL/ENTERAL THERAPY
4.4.4 PATIENT SEGMENTATION BY DISEASE PHASE (TYPE 1 FOCUS)
4.4.4.1 ACUTE PHASE (TYPE 1 SBS-IF)
4.4.4.2 ICU-MANAGED PATIENTS
4.4.4.3 HIGH PN UTILIZATION
4.4.4.4 ADAPTATION PHASE
4.4.4.5 TRANSITION TO ENTERAL NUTRITION
4.4.4.6 INITIATION OF GLP-2 THERAPY
4.4.4.7 RECOVERY / STABILIZATION PHASE
4.4.4.8 REDUCED PN DEPENDENCY
4.4.4.9 LONG-TERM MAINTENANCE
4.4.4.10 PATIENT SEGMENTATION BY CARE SETTING
4.4.4.11 HOSPITAL-BASED PATIENTS
4.4.4.12 ICU
4.4.4.13 SURGICAL WARDS
4.4.4.14 HOME CARE PATIENTS
4.4.4.15 HOME PARENTERAL NUTRITION (HPN)
4.4.4.16 SPECIALTY CENTERS
4.4.4.17 INTESTINAL REHABILITATION CENTERS
4.4.5 PATIENT SEGMENTATION BY DEMOGRAPHICS
4.4.5.1 AGE GROUP
4.4.5.2 NEONATES
4.4.5.3 PEDIATRIC
4.4.5.4 ADULTS
4.4.5.5 GERIATRIC
4.4.5.6 GENDER
4.4.5.7 MALE
4.4.5.8 FEMALE
4.4.6 PATIENT SEGMENTATION BY ETIOLOGY
4.4.6.1 ADULT ETIOLOGY
4.4.6.2 CROHN'S DISEASE
4.4.6.3 MESENTERIC ISCHEMIA
4.4.6.4 SURGICAL RESECTIONS
4.4.6.5 ONCOLOGY-RELATED
4.4.6.6 PEDIATRIC ETIOLOGY
4.4.6.7 NECROTIZING ENTEROCOLITIS (NEC)
4.4.6.8 CONGENITAL DEFECTS (ATRESIA, GASTROSCHISIS)
4.4.7 GEOGRAPHIC PATIENT DISTRIBUTION
4.4.7.1 NORTH AMERICA
4.4.7.2 U.S.
4.4.7.3 CANADA
4.4.7.4 EUROPE
4.4.7.5 GERMANY
4.4.7.6 FRANCE
4.4.7.7 UK
4.4.7.8 ITALY
4.4.7.9 SPAIN
4.4.7.10 ASIA-PAIFIC
4.4.7.11 JAPAN
4.4.7.12 CHINA
4.4.7.13 INDIA
4.4.8 TREATMENT PENETRATION & UTILIZATION RATES
4.4.8.1 PN PENETRATION RATE
4.4.8.2 % OF SBS-IF PATIENTS ON PN
4.4.8.3 GLP-2 PENETRATION RATE
4.4.8.4 % OF ELIGIBLE PATIENTS RECEIVING GLP-2
4.4.8.5 SUPPORTIVE THERAPY PENETRATION
4.4.8.6 ANTI-DIARRHEAL USAGE RATE
4.4.8.7 PPI USAGE RATE
4.4.8.8 PATIENT-LEVEL COST MODELING
4.4.8.9 ANNUAL COST PER PATIENT
4.4.8.10 PN COST (HOSPITAL VS HOME)
4.4.8.11 GLP-2 THERAPY COST
4.4.8.12 SUPPORTIVE THERAPY COST
4.4.9 COST BY PATIENT TYPE
4.4.9.1 PN-DEPENDENT
4.4.9.2 GLP-2 TREATED
4.4.9.3 TRANSPLANT
4.4.9.4 OUTPUT DELIVERABLES (EXCEL – CLIENT CRITICAL)
4.4.9.5 TOTAL SBS-IF PATIENTS (BY COUNTRY)
4.4.9.6 DIAGNOSED VS TREATED PATIENTS
4.4.9.7 PN-DEPENDENT PATIENTS
4.4.9.8 GLP-2 TREATED PATIENTS
4.4.9.9 TREATMENT PENETRATION RATES
4.4.9.10 AVERAGE ANNUAL COST PER THERAPY
4.5 INDUSTRY INSIGHTS
4.5.1 INTRODUCTION
4.5.2 INDUSTRY STRUCTURE OVERVIEW
4.5.3 MICRO AND MACRO ECONOMIC FACTORS
4.5.4 PENETRATION AND GROWTH PROSPECT MAPPING
4.5.5 KEY PRICING STRATEGIES
4.5.6 INTERVIEWS WITH SPECIALISTS
4.5.7 ANALYSIS AND RECOMMENDATION
4.5.8 CONCLUSION
4.6 WAR-DRIVEN DISRUPTION IN PHARMACEUTICAL SUPPLY CHAINS, GEOGRAPHIC FOOTPRINTS, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES
4.6.1 INTRODUCTION
4.6.2 SUPPLY CHAIN RESILIENCE
4.6.2.1 DIVERSIFICATION OF INGREDIENT AND PN/DRUG SUPPLIERS
4.6.2.2 ESTABLISHMENT OF REGIONAL PRODUCTION HUBS
4.6.2.3 STRATEGIC STOCKPILING OF CRITICAL PN BAGS, GLP-2 ANALOGUES, AND MEDICAL DEVICES
4.6.2.4 DEVELOPMENT OF ALTERNATIVE LOGISTICS AND COLD CHAIN ROUTES
4.6.2.5 STRATEGIC PARTNERSHIPS WITH LEADING CDMOS (E.G., CATALENT, LONZA)
4.6.2.6 EXPANSION OF MANUFACTURING, FILL-FINISH, AND PACKAGING CAPABILITIES FOR PN & GLP-2
4.6.3 ENERGY & MANUFACTURING OPERATIONAL COST RISK
4.6.3.1 RISING ENERGY COSTS IN PARENTERAL NUTRITION & DRUG FACILITIES
4.6.3.2 INCREASED COSTS FOR RAW MATERIALS, LIPID EMULSIONS, AND PHARMACEUTICALS
4.6.3.3 LONG-TERM ENERGY PROCUREMENT STRATEGIES FOR PN MANUFACTURERS
4.6.3.4 ADOPTION OF ENERGY-EFFICIENT MANUFACTURING TECHNOLOGIES
4.6.3.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS SYSTEMS
4.6.3.6 INTEGRATION OF RENEWABLE ENERGY IN MANUFACTURING FACILITIES
4.6.4 GEOGRAPHIC FOOTPRINT REASSESSMENT
4.6.4.1 EXPANSION OF MANUFACTURING IN STABLE REGIONS
4.6.4.2 DIVERSIFICATION OF NORTH AMERICA PN/GLP-2 PRODUCTION SITES
4.6.4.3 RELOCATION OF KEY INPUT/INTERMEDIATE PRODUCTION
4.6.4.4 EXPANSION INTO EMERGING MARKETS WITH HIGH SBS-IF BURDEN
4.6.4.5 ESTABLISHMENT OF REGIONAL COLD CHAIN TRANSIT AND DISTRIBUTION HUBS
4.6.5 SCENARIO PLANNING & RISK MANAGEMENT
4.6.5.1 DEVELOPMENT OF SUPPLY CHAIN CONTINGENCY PLANS
4.6.5.2 MULTI-SOURCE PROCUREMENT STRATEGIES FOR PN/GLP-2
4.6.5.3 GOVERNMENT AND HEALTH AUTHORITY COLLABORATIONS
4.6.5.4 CRISIS-RESPONSE SUPPLY NETWORKS FOR CRITICAL THERAPIES
4.6.5.5 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS IN SBS-IF MARKET
4.6.6 CASH & FINANCIAL PROTECTION
4.6.7 STRENGTHENING CAPITAL RESERVES FOR PN & BIOPHARMA EXPANSION
4.6.7.1 DIVERSIFICATION OF PRODUCT PORTFOLIOS AND REVENUE STREAMS
4.6.7.2 INVESTMENTS IN DOMESTIC PRODUCTION INFRASTRUCTURE
4.6.7.3 GOVERNMENT INCENTIVES AND PUBLIC-PRIVATE PARTNERSHIPS
4.6.7.4 LONG-TERM PROCUREMENT CONTRACTS WITH HEALTHCARE SYSTEMS
4.6.8 DATA PROTECTION
4.6.8.1 DATA PROTECTION FRAMEWORKS FOR CLINICAL AND REAL-WORLD SBS-IF DATA
4.6.8.2 PROTECTION OF CLINICAL TRIAL DATA, PATIENT DATA, AND DRUG DEVELOPMENT
4.6.8.3 SECURE CLOUD INFRASTRUCTURE FOR SBS-IF DATA MANAGEMENT
4.6.8.4 AI-DRIVEN THREAT DETECTION IN MARKET RESEARCH AND PHARMA NETWORKS
4.6.8.5 COMPLIANCE WITH PHARMACEUTICAL DATA REGULATIONS & GXP
4.6.9 NEW BUSINESS AND EMERGING REVENUE OPPORTUNITIES & FUTURE OUTLOOK
4.6.10 CONCLUSION
4.7 EPIDEMIOLOGY
4.7.1 INTRODUCTION
4.7.2 INCIDENCE OF TYPE 1 SBS-IF BY GENDER
4.7.3 TREATMENT RATE
4.7.4 MORTALITY RATE
4.7.5 TREATMENT ADHERENCE AND SWITCH MODEL
4.7.6 PATIENT TREATMENT SUCCESS RATES
4.7.7 CONCLUSION
4.8 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NORTH AMERICA TYPE 1 SBS-IF MARKET
4.9 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – NORTH AMERICA TYPE 1 SBS-IF MARKET
4.1 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – NORTH AMERICA TYPE 1 SBS-IF MARKET
4.11 PIPELINE ANALYSIS
4.11.1 INTRODUCTION
4.11.2 CLINICAL TRIALS AND PHASE ANALYSIS
4.11.3 DRUG & BIOTHERAPY PIPELINE
4.11.4 PHASE III CANDIDATES (E.G., APRAGLUTIDE)
4.11.5 PHASE II CANDIDATES (E.G., LONG-ACTING GLP-2)
4.11.6 PHASE I CANDIDATES (EMERGING REGENERATIVE/CELLULAR)
4.11.7 OTHERS (PRE-CLINICAL, EN FORMULATION PIPELINE)
4.11.8 CONCLUSION
4.12 PIPELINE ANALYSIS
4.12.1 INTRODUCTION
4.12.2 TAKEDA PHARMACEUTICAL COMPANY – R&D LEADERSHIP IN INTESTINAL REGENERATION THERAPIES
4.12.3 BAXTER INTERNATIONAL – PARENTERAL NUTRITION AND INFUSION SYSTEM INNOVATION
4.12.4 FRESENIUS KABI AG – CLINICAL NUTRITION AND INJECTABLE THERAPY DEVELOPMENT
4.12.5 NESTLÉ HEALTH SCIENCE – MEDICAL NUTRITION AND GUT ADAPTATION RESEARCH
4.12.6 ABBOTT LABORATORIES – INTEGRATED NUTRITION AND METABOLIC MONITORING SOLUTIONS
4.12.7 CONCLUSION
4.13 MARKETED THERAPY ANALYSIS
4.13.1 INTRODUCTION
4.13.2 DRUG/THERAPY
4.13.2.1 BRAND NAME
4.13.2.2 GENERICS NAME
4.13.3 PHARMACOLOGICAL CLASSIFICATION
4.13.4 PRIMARY INDICATION
4.13.5 MARKET STATUS
4.13.6 MEDICATION TYPE
4.13.7 DOSAGE FORM
4.13.8 DOSAGE AVAILABILITY
4.13.9 PACKAGING TYPE
4.13.10 ROUTE OF ADMINISTRATION
4.13.11 DOSING FREQUENCY
4.13.12 THERAPY INSIGHT
4.13.13 AN OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES, REGULATORY MILESTONES, SAFETY/EFFICACY, MARKET EXCLUSIVITY DATA
4.13.14 FORECAST MARKET OUTLOOK
4.13.14.1 CROSS COMPETITION
4.13.14.2 THERAPEUTIC PORTFOLIO
4.13.14.3 CURRENT DEVELOPMENT SCENARIO
4.13.15 CONCLUSION
4.14 PIPELINE ANALYSIS - NORTH AMERICA TYPE 1 SBS-IF TREATMENT MARKET
4.14.1 CLINICAL TRIALS AND PHASE ANALYSIS
4.14.2 DRUG AND BIOTHERAPY PIPELINE
4.14.3 PHASE III CANDIDATES
4.14.4 PHASE II CANDIDATES
4.14.5 PHASE I CANDIDATES
4.14.6 OTHERS (PRE-CLINICAL AND RESEARCH STAGE)
4.15 R & D ANALYSIS
4.15.1 COMPARATIVE ANALYSIS
4.15.2 DEVELOPMENTAL LANDSCAPE
4.15.3 INSIGHTS ON REGULATORY MILESTONES
4.15.4 THERAPEUTIC ASSESSMENT
4.15.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
5 HEALTHCARE TARIFFS IMPACT ANALYSIS
5.1 OVERVIEW
5.2 TARIFF STRUCTURES
5.2.1 NORTH AMERICA VS. REGIONAL TARIFF STRUCTURES
5.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES
5.2.3 ASIA-PACIFIC: GOVERNMENT TARIFFS ON IMPORTED PN/DRUG THERAPIES
5.2.4 EMERGING MARKETS: TARIFF CHALLENGES FOR NUTRITION & BIOLOGICS
5.2.5 MAJOR MARKET UPTAKE
5.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
5.3.1 IMPORT DUTIES ON PN KITS, GLP-2 VS. GENERICS
5.3.2 IMPACT ON AFFORDABILITY & ACCESS
5.3.3 KEY TRADE AGREEMENTS AFFECTING SBS-IF PRODUCTS
5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS/PATIENTS
5.4.1 COST BURDEN ON HOSPITALS AND FACILITIES
5.4.2 EFFECT ON PATIENT AFFORDABILITY & INSURANCE COVERAGE
5.4.3 ROLE IN MEDICAL TOURISM FOR ADVANCED SBS-IF THERAPIES
5.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
5.5.1 WTO REGULATIONS
5.5.2 TRADE WARS IMPACT ON SUPPLY CHAIN
5.5.3 FTAS IN REDUCING TARIFFS
5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
6 MARKET ACCESS
6.1 10-YEAR MARKET FORECAST
6.2 CLINICAL TRIAL RECENT UPDATES
6.3 ANNUAL NEW FDA APPROVALS FOR SBS-IF TREATMENTS
6.4 MANUFACTURERS, DISTRIBUTORS, AND DEALS
6.5 MAJOR MARKET UPTAKE
6.6 CURRENT TREATMENT PRACTICES
6.7 IMPACT OF UPCOMING THERAPIES
7 REGULATORY FRAMEWORK–
7.1 INTRODUCTION
7.2 REGULATORY APPROVAL PROCESS
7.3 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
7.4 REGULATORY APPROVAL PATHWAYS
7.5 LICENSING AND REGISTRATION
7.6 POST-MARKETING SURVEILLANCE
7.7 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
7.8 CONCLUSION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING SBS-IF PATIENT POPULATION
8.1.2 GROWING ADOPTION OF GLP-2 THERAPIES
8.1.3 INCREASING GOVERNMENT & ORPHAN DRUG SUPPORT
8.2 RESTRAINTS
8.2.1 HIGH COST OF SBS-IF TREATMENT
8.2.2 LIMITE.D AWARENESS & DELAYED DIAGNOSIS
8.3 OPPORTUNITIES
8.3.1 COMPLEX MULTIDISCIPLINARY PATIENT MANAGEMENT
8.3.2 STRINGENT REGULATORY APPROVAL PROCESSES
8.4 CHALLENGES
8.4.1 ADVANCEMENTS IN REGENERATIVE MEDICINE
8.4.2 EXPANSION OF HOME-BASED NUTRITIONAL CARE
9 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY
9.1 OVERVIEW
9.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
9.2.1 NUTRITIONAL SUPPORT THERAPY
9.2.2 PHARMACOLOGICAL THERAPY
9.2.3 SURGICAL & INTERVENTIONAL TREATMENT
9.2.4 EMERGING & ADVANCED THERAPIES
9.3 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.3.1 PARENTERAL NUTRITION (PN)
9.3.2 ENTERAL NUTRITION (EN)
9.3.3 PN COMPOSITION
9.4 NORTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.4.1 HOME PARENTERAL NUTRITION (HPN)
9.4.2 PERIPHERAL PARENTERAL NUTRITION (PPN)
9.4.3 CYCLIC PARENTERAL NUTRITION
9.5 NORTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.5.1 HOSPITAL-BASED TPN
9.5.2 ICU-BASED TPN
9.6 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
9.6.1 ADULT HPN
9.6.2 PEDIATRIC HPN
9.7 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
9.7.1 LONG-TERM HPN
9.7.2 SHORT-TERM HPN
9.8 NORTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.8.1 ORAL FEEDING
9.8.2 TUBE FEEDING
9.8.3 FORMULA TYPE
9.9 NORTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.9.1 NASOGASTRIC (NG)
9.9.2 PEG FEEDING
9.9.3 JEJUNOSTOMY FEEDING
9.1 NORTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.10.1 POLYMERIC
9.10.2 ELEMENTAL
9.10.3 SEMI-ELEMENTAL
9.11 NORTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.11.1 MACRONUTRIENTS
9.11.2 ELECTROLYTES & FLUIDS
9.11.3 MICRONUTRIENTS
9.12 NORTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.12.1 AMINO ACIDS
9.12.2 LIPID EMULSIONS
9.12.3 DEXTROSE
9.13 NORTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.13.1 VITAMINS
9.13.2 TRACE ELEMENTS
9.14 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.14.1 NORTH AMERICA
9.14.2 EUROPE
9.14.3 ASIA-PACIFIC
9.14.4 MIDDLE EAST AND AFRICA
9.14.5 SOUTH AMERICA
9.15 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.15.1 HORMONAL & INTESTINAL ADAPTATION THERAPY
9.15.2 ANTI-DIARRHEAL THERAPY
9.15.3 ANTI-SECRETORY THERAPY
9.15.4 MICRONUTRIENT SUPPLEMENTATION
9.15.5 ANTI-INFECTIVE THERAPY
9.15.6 BILE ACID & ABSORPTION MODIFIERS
9.16 NORTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.16.1 GLP-2 ANALOGUES
9.16.2 GROWTH HORMONE THERAPY
9.16.3 IGF-1 & ANALOGUES
9.17 NORTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.17.1 TEDUGLUTIDE
9.17.2 APRAGLUTIDE (LATE-STAGE)
9.17.3 LONG-ACTING GLP-2 ANALOGUES
9.18 NORTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
9.18.1 HUMATROPE
9.18.2 NORDITROPIN
9.18.3 GENOTROPIN
9.19 NORTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.19.1 INCRELEX
9.19.2 OTHERS
9.2 NORTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.20.1 OPIOID-BASED
9.20.2 NON-OPIOID AGENTS
9.21 NORTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.21.1 LOPERAMIDE
9.21.2 CODEINE
9.22 NORTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.22.1 PROTON PUMP INHIBITORS
9.22.2 SOMATOSTATIN ANALOGUES
9.22.3 H2 RECEPTOR ANTAGONISTS
9.23 NORTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.23.1 OMEPRAZOLE
9.23.2 PANTOPRAZOLE
9.23.3 ESOMEPRAZOLE
9.23.4 OTHERS
9.24 NORTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
9.24.1 OCTREOTIDE
9.24.2 OTHERS
9.25 NORTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.25.1 FAMOTIDINE
9.25.2 OTHERS
9.26 NORTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.26.1 FAT-SOLUBLE VITAMINS (A, D, E, K)
9.26.2 ELECTROLYTES
9.26.3 VITAMIN B12
9.26.4 MINERAL SUPPLEMENTATION
9.27 NORTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.27.1 BROAD-SPECTRUM ANTIBIOTICS
9.27.2 SIBO-TARGETED THERAPY
9.28 NORTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.28.1 BILE ACID SEQUESTRANTS
9.28.2 FAT ABSORPTION ENHANCERS
9.29 NORTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.29.1 CHOLESTYRAMINE
9.29.2 COLESEVELAM
9.29.3 OTHERS
9.3 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.30.1 NORTH AMERICA
9.30.2 EUROPE
9.30.3 ASIA-PACIFIC
9.30.4 MIDDLE EAST AND AFRICA
9.30.5 SOUTH AMERICA
9.31 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.31.1 INTESTINAL LENGTHENING PROCEDURES
9.31.2 OSTOMY & RECONSTRUCTION
9.31.3 INTESTINAL TRANSPLANTATION
9.32 NORTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.32.1 STEP PROCEDURE
9.32.2 BIANCHI PROCEDURE
9.33 NORTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.33.1 ILEOSTOMY
9.33.2 JEJUNOSTOMY
9.33.3 REVERSAL SURGERY
9.34 NORTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.34.1 ISOLATED SMALL BOWEL
9.34.2 LIVER + INTESTINE
9.34.3 MULTIVISCERAL TRANSPLANT
9.35 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.35.1 NORTH AMERICA
9.35.2 EUROPE
9.35.3 ASIA-PACIFIC
9.35.4 MIDDLE EAST AND AFRICA
9.35.5 SOUTH AMERICA
9.36 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.36.1 REGENERATIVE MEDICINE
9.36.2 MICROBIOME-BASED THERAPY
9.36.3 GENE THERAPY
9.37 NORTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.37.1 STEM CELL THERAPY
9.37.2 TISSUE-ENGINEERED INTESTINE
9.38 NORTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.38.1 PROBIOTICS
9.38.2 FMT
9.39 NORTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.39.1 ABSORPTIVE FUNCTION TARGETING
9.39.2 MUCOSAL GROWTH MODULATION
9.4 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.40.1 NORTH AMERICA
9.40.2 EUROPE
9.40.3 ASIA-PACIFIC
9.40.4 MIDDLE EAST AND AFRICA
9.40.5 SOUTH AMERICA
10 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION
10.1 OVERVIEW
10.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
10.2.1 CORE SBS-IF MARKET
10.2.2 SBS-IF ATTRIBUTABLE MARKET
10.2.3 ADJACENT / NON-SPECIFIC MARKET
10.3 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
10.3.1 PARENTERAL NUTRITION
10.3.2 GLP-2 ANALOGUES
10.4 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.4.1 NORTH AMERICA
10.4.2 EUROPE
10.4.3 ASIA-PACIFIC
10.4.4 MIDDLE EAST AND AFRICA
10.4.5 SOUTH AMERICA
10.5 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
10.5.1 ANTI-DIARRHEALS
10.5.2 PPIS
10.5.3 ANTIBIOTICS
10.6 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.6.1 NORTH AMERICA
10.6.2 EUROPE
10.6.3 ASIA-PACIFIC
10.6.4 MIDDLE EAST AND AFRICA
10.6.5 SOUTH AMERICA
10.7 NORTH AMERICA ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.7.1 NORTH AMERICA
10.7.2 EUROPE
10.7.3 ASIA-PACIFIC
10.7.4 MIDDLE EAST AND AFRICA
10.7.5 SOUTH AMERICA
11 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE
11.1 OVERVIEW
11.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
11.2.1 ACUTE PHASE (TYPE 1 SBS-IF)
11.2.2 ADAPTATION PHASE
11.2.3 RECOVERY PHASE
11.3 NORTH AMERICA ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
11.3.1 NORTH AMERICA
11.3.2 EUROPE
11.3.3 ASIA-PACIFIC
11.3.4 MIDDLE EAST AND AFRICA
11.3.5 SOUTH AMERICA
11.4 NORTH AMERICA ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
11.4.1 NORTH AMERICA
11.4.2 EUROPE
11.4.3 ASIA-PACIFIC
11.4.4 MIDDLE EAST AND AFRICA
11.4.5 SOUTH AMERICA
11.5 NORTH AMERICA RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
11.5.1 NORTH AMERICA
11.5.2 EUROPE
11.5.3 ASIA-PACIFIC
11.5.4 MIDDLE EAST AND AFRICA
11.5.5 SOUTH AMERICA
12 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
12.2.1 ADULT
12.2.2 PEDIATRIC
12.3 NORTH AMERICA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
12.3.1 NORTH AMERICA
12.3.2 EUROPE
12.3.3 ASIA-PACIFIC
12.3.4 MIDDLE EAST AND AFRICA
12.3.5 SOUTH AMERICA
12.4 NORTH AMERICA PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
12.4.1 NORTH AMERICA
12.4.2 EUROPE
12.4.3 ASIA-PACIFIC
12.4.4 MIDDLE EAST AND AFRICA
12.4.5 SOUTH AMERICA
13 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
13.2.1 INTRAVENOUS
13.2.2 SUBCUTANEOUS
13.2.3 ORAL
13.2.4 ENTERAL
13.3 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
13.3.1 PN
13.3.2 INJECTABLES
13.4 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.4.1 NORTH AMERICA
13.4.2 EUROPE
13.4.3 ASIA-PACIFIC
13.4.4 MIDDLE EAST AND AFRICA
13.4.5 SOUTH AMERICA
13.5 NORTH AMERICA SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.5.1 NORTH AMERICA
13.5.2 EUROPE
13.5.3 ASIA-PACIFIC
13.5.4 MIDDLE EAST AND AFRICA
13.5.5 SOUTH AMERICA
13.6 NORTH AMERICA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.6.1 NORTH AMERICA
13.6.2 EUROPE
13.6.3 ASIA-PACIFIC
13.6.4 MIDDLE EAST AND AFRICA
13.6.5 SOUTH AMERICA
13.7 NORTH AMERICA ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.7.1 NORTH AMERICA
13.7.2 EUROPE
13.7.3 ASIA-PACIFIC
13.7.4 MIDDLE EAST AND AFRICA
13.7.5 SOUTH AMERICA
14 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
14.2.1 HOSPITALS (ACUTE CARE)
14.2.2 HOME CARE (HPN PROGRAMS)
14.2.3 ICU SETTINGS
14.2.4 PECIALTY GI CENTERS
14.2.5 PEDIATRIC SPECIALTY HOSPITALS
14.3 NORTH AMERICA HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.3.1 NORTH AMERICA
14.3.2 EUROPE
14.3.3 ASIA-PACIFIC
14.3.4 MIDDLE EAST AND AFRICA
14.3.5 SOUTH AMERICA
14.4 NORTH AMERICA HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.4.1 NORTH AMERICA
14.4.2 EUROPE
14.4.3 ASIA-PACIFIC
14.4.4 MIDDLE EAST AND AFRICA
14.4.5 SOUTH AMERICA
14.5 NORTH AMERICA ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.5.1 NORTH AMERICA
14.5.2 EUROPE
14.5.3 ASIA-PACIFIC
14.5.4 MIDDLE EAST AND AFRICA
14.5.5 SOUTH AMERICA
14.6 NORTH AMERICA SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.6.1 NORTH AMERICA
14.6.2 EUROPE
14.6.3 ASIA-PACIFIC
14.6.4 MIDDLE EAST AND AFRICA
14.6.5 SOUTH AMERICA
14.7 NORTH AMERICA PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.7.1 NORTH AMERICA
14.7.2 EUROPE
14.7.3 ASIA-PACIFIC
14.7.4 MIDDLE EAST AND AFRICA
14.7.5 SOUTH AMERICA
15 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
15.2.1 HOSPITAL PHARMACY
15.2.2 SPECIALTY PHARMACY
15.2.3 RETAIL PHARMACY
15.2.4 ONLINE PHARMACY
15.3 NORTH AMERICA HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
15.3.1 NORTH AMERICA
15.3.2 EUROPE
15.3.3 ASIA-PACIFIC
15.3.4 MIDDLE EAST AND AFRICA
15.3.5 SOUTH AMERICA
15.4 NORTH AMERICA SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
15.4.1 NORTH AMERICA
15.4.2 EUROPE
15.4.3 ASIA-PACIFIC
15.4.4 MIDDLE EAST AND AFRICA
15.4.5 SOUTH AMERICA
15.5 NORTH AMERICA RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
15.5.1 NORTH AMERICA
15.5.2 EUROPE
15.5.3 ASIA-PACIFIC
15.5.4 MIDDLE EAST AND AFRICA
15.5.5 SOUTH AMERICA
16 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY LANDSCAPE
17.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL
18 SWOT ANALYSIS
19 COMPANY PROFILES
19.1 FRESENIUS KABI
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 BAXTER INTERNATIONAL INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 NESTLÉ HEALTH SCIENCE
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 ABBOTT LABORATORIES
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 MOOG COMPANY
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT/NEWS
19.7 ACULIFE HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 AMSINO INTERNATIONAL, INC
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 AURORA HEALTH CARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 AMERIPHARMA SPECIALTY CARE.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 BAUSCH HEALTH COMPANIES INC
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 BEVELRYHILLS DIGESTIVE CARE
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 B. BRAUN SE
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 CAMVITTA
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 CHOICE PARENTERAL NUTRITION LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 CONTINUUMRX
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 FERRING PHARMACEUTICALS
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 GRIFOLS S.A.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 HIKMA PHARMACEUTICALS
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.2 HOSPIRA (PART OF PFIZER INC.)
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
19.21 HANMI PHARM.CO.,LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENT
19.22 ICU MEDICAL, INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENT
19.23 INFUSION SOLUTIONS
19.23.1 COMPANY SNAPSHOT
19.23.2 PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENT
19.24 INTEGRATED CARE SYSTEMS
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 JEDUX PARENTERAL PRIVATE LIMITED
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENT
19.26 LABORATOIRE DIELEN
19.26.1 COMPANY SNAPSHOT
19.26.2 PRODUCT PORTFOLIO
19.26.3 RECENT DEVELOPMENT
19.27 NAPO THERAPEUTICS.
19.27.1 COMPANY SNAPSHOT
19.27.2 PRODUCT PORTFOLIO
19.27.3 RECENT DEVELOPMENT/NEWS
19.28 NUTREGO
19.28.1 COMPANY SNAPSHOT
19.28.2 PRODUCT PORTFOLIO
19.28.3 RECENT DEVELOPMENT
19.29 NUTRICIA (DANONE GROUP)
19.29.1 COMPANY SNAPSHOT
19.29.2 REVENUE ANALYSIS
19.29.3 PRODUCT PORTFOLIO
19.29.4 RECENT DEVELOPMENT
19.3 NUTRICIA NORTH AMERICA
19.30.1 COMPANY SNAPSHOTS
19.30.2 PRODUCT PORTFOLIO
19.30.3 RECENT DEVELOPMENT
19.31 NUTRISHARE
19.31.1 COMPANY SNAPSHOT
19.31.2 PRODUCT PORTFOLIO
19.31.3 RECENT DEVELOPMENT
19.32 OXTHERA
19.32.1 COMPANY SNAPSHOT
19.32.2 PRODUCT PORTFOLIO
19.32.3 RECENT DEVELOPMENT
19.33 PHARMKO, INC.
19.33.1 COMPANY SNAPSHOT
19.33.2 PRODUCT PORTFOLIO
19.33.3 RECENT DEVELOPMENT
19.34 PUERTO LIFE SCIENCES PVT. LTD.
19.34.1 COMPANY SNAPSHOT
19.34.2 PRODUCT PORTFOLIO
19.34.3 RECENT DEVELOPMENT
19.35 SHANDONG QIDU PHARMACEUTICAL CO., LTD.
19.35.1 COMPANY SNAPSHOT
19.35.2 PRODUCT PORTFOLIO
19.35.3 RECENT DEVELOPMENT
19.36 STANFORD HEALTH CARE
19.36.1 COMPANY SNAPSHOT
19.36.2 PRODUCT PORTFOLIO
19.36.3 RECENT DEVELOPMENT
19.37 UF HEALTH
19.37.1 COMPANY SNAPSHOT
19.37.2 PRODUCT PORTFOLIO
19.37.3 RECENT DEVELOPMENT
19.38 IRONWOOD PHARMACEUTICALS
19.38.1 COMPANY SNAPSHOT
19.38.2 REVENUE ANALYSIS
19.38.3 PRODUCT PORTFOLIO
19.38.4 RECENT DEVELOPMENT
19.39 VISION PARENTERAL
19.39.1 COMPANY SNAPSHOT
19.39.2 PRODUCT PORTFOLIO
19.39.3 RECENT DEVELOPMENT
19.4 ZEALAND PHARMA
19.40.1 COMPANY SNAPSHOT
19.40.2 REVENUE ANALYSIS
19.40.3 PRODUCT PORTFOLIO
19.40.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 TREATMENT RATE OF SBI-IF PATIENTS
TABLE 2 ESTIMATED THERAPY-SPECIFIC PATIENT POOLS
TABLE 3 ESTIMATED FUNNEL PATEGINTS
TABLE 4 KEY INDUSTRY INSIGHTS AND MARKET TRENDS IN THE NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET
TABLE 5 IMPACT OF WAR-DRIVEN DISRUPTIONS ON THE NORTH AMERICA TYPE 1 SBS-IF TREATMENT MARKET ECOSYSTEM AND INDUSTRY RESPONSE FRAMEWORK
TABLE 6 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NORTH AMERICA TYPE 1 SBS-IF MARKET
TABLE 7 DISTRIBUTION OF OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE – NORTH AMERICA TYPE 1 SBS-IF MARKET
TABLE 8 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE – NORTH AMERICA TYPE 1 SBS-IF MARKET
TABLE 9 PIPELINE LANDSCAPE AND CLINICAL DEVELOPMENT OVERVIEW
TABLE 10 TOP ENTITIES BASED ON R&D GLANCE – NORTH AMERICA TYPE 1 SBS-IF TREATMENT MARKET
TABLE 11 PRECLINICAL / RESEARCH STAGE VACCINE CANDIDATES
TABLE 12 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 13 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 14 NORTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 15 NORTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 17 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 18 NORTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 19 NORTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 20 NORTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 21 NORTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 22 NORTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 23 NORTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 24 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 25 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 26 NORTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 27 NORTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 28 NORTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 29 NORTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 30 NORTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 31 NORTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 32 NORTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 33 NORTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 34 NORTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 35 NORTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 36 NORTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 37 NORTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 38 NORTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 NORTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 40 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 41 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 42 NORTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 43 NORTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 44 NORTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 45 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 46 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 47 NORTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 48 NORTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 49 NORTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 50 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 51 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 52 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 53 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 54 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 55 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 56 NORTH AMERICA ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 57 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 58 NORTH AMERICA ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 59 NORTH AMERICA ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 60 NORTH AMERICA RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 61 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 62 NORTH AMERICA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 63 NORTH AMERICA PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 64 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 65 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 66 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 67 NORTH AMERICA SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 68 NORTH AMERICA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 69 NORTH AMERICA ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 70 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 71 NORTH AMERICA HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 72 NORTH AMERICA HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 73 NORTH AMERICA ICU SETTINGS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 74 NORTH AMERICA SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 75 NORTH AMERICA PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 76 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 77 NORTH AMERICA HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 78 NORTH AMERICA SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 79 NORTH AMERICA RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 80 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)
TABLE 81 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 82 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 83 NORTH AMERICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 84 NORTH AMERICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 85 NORTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 86 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 87 NORTH AMERICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 88 NORTH AMERICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 89 NORTH AMERICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 90 NORTH AMERICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 91 NORTH AMERICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 NORTH AMERICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 93 NORTH AMERICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 94 NORTH AMERICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 95 NORTH AMERICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 96 NORTH AMERICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 97 NORTH AMERICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 98 NORTH AMERICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 99 NORTH AMERICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 100 NORTH AMERICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 101 NORTH AMERICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 102 NORTH AMERICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 103 NORTH AMERICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 104 NORTH AMERICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 105 NORTH AMERICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 106 NORTH AMERICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 107 NORTH AMERICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 108 NORTH AMERICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 109 NORTH AMERICA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 110 NORTH AMERICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 111 NORTH AMERICA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 112 NORTH AMERICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 113 NORTH AMERICA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 114 NORTH AMERICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 115 NORTH AMERICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 116 NORTH AMERICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 117 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 118 NORTH AMERICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 119 NORTH AMERICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 120 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 121 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 122 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 123 NORTH AMERICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 124 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 125 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 126 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 127 US NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 128 US PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 129 US TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 130 US HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 131 US HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 132 US ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 133 US TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 134 US FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 135 US PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 136 US MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 137 US MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 138 US PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 139 US HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 140 US GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 141 US GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 142 US IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 143 US ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 144 US OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 US ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 146 US PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 147 US SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 148 US H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 149 US MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 150 US ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 151 US BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 152 US BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 153 US SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 US INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 155 US OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 156 US INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 157 US EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 158 US REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 159 US MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 160 US GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 161 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 162 US CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 163 US SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 164 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 165 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 166 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 167 US INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 168 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 169 US TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 170 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 171 CANADA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 172 CANADA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 173 CANADA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 174 CANADA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 175 CANADA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 176 CANADA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 177 CANADA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 178 CANADA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 179 CANADA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 CANADA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 CANADA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 182 CANADA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 183 CANADA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 184 CANADA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 185 CANADA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 186 CANADA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 187 CANADA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 188 CANADA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 189 CANADA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 190 CANADA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 191 CANADA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 192 CANADA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 193 CANADA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 194 CANADA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 195 CANADA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 196 CANADA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 197 CANADA SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 198 CANADA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 199 CANADA OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 200 CANADA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 201 CANADA EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 202 CANADA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 203 CANADA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 204 CANADA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 205 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 206 CANADA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 207 CANADA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 208 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 209 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 210 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 211 CANADA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 212 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 213 CANADA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 214 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 215 MEXICO NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 216 MEXICO PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 217 MEXICO TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 218 MEXICO HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 219 MEXICO HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 220 MEXICO ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 221 MEXICO TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 222 MEXICO FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 223 MEXICO PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 224 MEXICO MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 225 MEXICO MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 226 MEXICO PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 227 MEXICO HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 228 MEXICO GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 229 MEXICO GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 230 MEXICO IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 231 MEXICO ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 232 MEXICO OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 233 MEXICO ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 234 MEXICO PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 235 MEXICO SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 236 MEXICO H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 237 MEXICO MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 238 MEXICO ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 239 MEXICO BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 240 MEXICO BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 241 MEXICO SURGICAL & INTERVENTIONAL TREATMENT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 242 MEXICO INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 243 MEXICO OSTOMY & RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 244 MEXICO INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 245 MEXICO EMERGING & ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 246 MEXICO REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 247 MEXICO MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 248 MEXICO GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 249 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 250 MEXICO CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 251 MEXICO SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 252 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 253 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 254 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 255 MEXICO INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 256 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 257 MEXICO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: MULTIVARIVATE MODELING
FIGURE 10 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: PRODUCT TYPE TIMELINE CURVE
FIGURE 11 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: APPLICATION COVERAGE GRID
FIGURE 12 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION
FIGURE 13 FOUR SEGMENTS COMPRISE THE NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY (2025)
FIGURE 14 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 15 RISING SBS-IF PATIENT POPULATION IS EXPECTED TO DRIVE THE NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET DURING THE FORECAST PERIOD OF 2026 TO 2033.
FIGURE 16 NUTRITIONAL SUPPORT THERAPY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET IN 2026 & 2033
FIGURE 17 STRATEGIC DECISIONS
FIGURE 18 PESTEL ANALYSIS
FIGURE 19 DROC ANALYSIS
FIGURE 20 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY TREATMENT MODALITY, 2025
FIGURE 21 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY MARKET ATTRIBUTION, 2025
FIGURE 22 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISEASE MANAGEMENT PHASE, 2025
FIGURE 23 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY PATIENT TYPE, 2025
FIGURE 24 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025
FIGURE 25 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY END USER, 2025
FIGURE 26 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025
FIGURE 27 NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)
FIGURE 28 NORTH AMERICA NORTH AMERICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)
